Use of pegfilgrastim primary prophylaxis and risk of infection, by chemotherapy cycle and regimen, among patients with breast cancer or non-Hodgkin’s lymphoma

[1] Lyman GH(2010)Risk of mortality in patients with cancer who experience febrile neutropenia Cancer 116 5555-5563

[2] Michels SL(2008)Risk and timing of neutropenia events in adult cancer patients receiving chemotherapy: the results of a prospective nationwide study of oncology practice J Natl Compr Cancer Netw 6 109-118

[3] Reynolds MW(2006)Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients Cancer 106 2258-2266

[4] Crawford J(2007)Impact of primary prophylaxis with granulocyte colony-stimulating factor on febrile neutropenia and mortality in adult cancer patients receiving chemotherapy: a systematic review J Clin Oncol 25 3158-1184

[5] Dale DC(2005)Prevention of chemotherapy-induced febrile neutropenia by prophylactic antibiotics plus or minus granulocyte colony-stimulating factor in small-cell lung cancer: a Dutch randomized phase III study J Clin Oncol 23 7974-731

[6] Kuderer NM(2005)First and subsequent cycle use of pegfilgrastim prevents febrile neutropenia in patients with breast cancer: a multicenter, double-blind, placebo-controlled phase III study J Clin Oncol 23 1178-170

[7] Kuderer NM(2002)Blinded, randomized, multicenter study to evaluate single administration pegfilgrastim once per cycle versus daily filgrastim as an adjunct to chemotherapy in patients with high-risk stage II or stage III/IV breast cancer J Clin Oncol 20 727-v251

[8] Dale DC(1993)Randomized, double-blind, placebo-controlled, phase III study of recombinant human granulocyte-macrophage colony-stimulating factor as adjunct to induction treatment of high-grade malignant non-Hodgkin’s lymphomas Blood 82 2329-32

[9] Crawford J(1991)Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer N Engl J Med 325 164-3205

[10] Kuderer NM(2010)Hematopoietic growth factors: ESMO clinical practice guidelines for the applications Ann Oncol Suppl 5 v248-298

[1] Lyman GH(2010)Risk of mortality in patients with cancer who experience febrile neutropenia Cancer 116 5555-5563

[2] Michels SL(2008)Risk and timing of neutropenia events in adult cancer patients receiving chemotherapy: the results of a prospective nationwide study of oncology practice J Natl Compr Cancer Netw 6 109-118

[3] Reynolds MW(2006)Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients Cancer 106 2258-2266

[4] Crawford J(2007)Impact of primary prophylaxis with granulocyte colony-stimulating factor on febrile neutropenia and mortality in adult cancer patients receiving chemotherapy: a systematic review J Clin Oncol 25 3158-1184

[5] Dale DC(2005)Prevention of chemotherapy-induced febrile neutropenia by prophylactic antibiotics plus or minus granulocyte colony-stimulating factor in small-cell lung cancer: a Dutch randomized phase III study J Clin Oncol 23 7974-731

[6] Kuderer NM(2005)First and subsequent cycle use of pegfilgrastim prevents febrile neutropenia in patients with breast cancer: a multicenter, double-blind, placebo-controlled phase III study J Clin Oncol 23 1178-170

[7] Kuderer NM(2002)Blinded, randomized, multicenter study to evaluate single administration pegfilgrastim once per cycle versus daily filgrastim as an adjunct to chemotherapy in patients with high-risk stage II or stage III/IV breast cancer J Clin Oncol 20 727-v251

[8] Dale DC(1993)Randomized, double-blind, placebo-controlled, phase III study of recombinant human granulocyte-macrophage colony-stimulating factor as adjunct to induction treatment of high-grade malignant non-Hodgkin’s lymphomas Blood 82 2329-32

[9] Crawford J(1991)Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer N Engl J Med 325 164-3205

[10] Kuderer NM(2010)Hematopoietic growth factors: ESMO clinical practice guidelines for the applications Ann Oncol Suppl 5 v248-298